Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says

Clinical Trial Shows TD139 as a Promising Therapy Against Pulmonary Fibrosis, Maker Says

Clinical trial results indicate that inhaled TD139 is an effective, safe and well-tolerated treatment for idiopathic pulmonary fibrosis (IPF), its maker, Galecto Biotech AB, has reported. The phase 1b/2a clinical trial (NCT02257177) was divided into two parts. Part 1 was a randomized, double-blind, single-center, placebo-controlled, single ascending dose phase 1…

Synairgen Releases Data Showing Early Potential for LOXL2 Inhibitor to Treat IPF

Synairgen released further positive data from its lysyl oxidase-like 2 enzyme (LOXL2) inhibitor program to treat idiopathic pulmonary fibrosis (IPF), being conducted in collaboration with Pharmaxis. A Phase 1 clinical trial is set to start this year, if toxicology studies are successfully completed. Synairgen and Pharmaxis entered a collaboration in August…

6 Common Symptoms of Chronic Fatigue

If you suffer from a chronic illness, then it’s highly likely that you’ll experience fatigue from time to time. Fatigue is different than just feeling tired, and generally it’s not something that can be fixed with an early night or by resting for a little while. With tips from the pros at …

Please Give Me Grace; I Am Trying My Best

This column comes from a place of physical and emotional exhaustion, so please bear with me. I know I’ll regain the physical strength in a couple of days, and I know the emotional toll will decrease as well, and I’ll see things a little more clearly soon enough. As Annie…

Dealing with Abnormal Symptoms is Exhausting

When you’re living with a life-threatening illness such as idiopathic pulmonary fibrosis (IPF), it often feels like everything is on overdrive. What I mean is that I often feel oversensitive to the comments people make, or how they might react to seeing me on oxygen, and this…